Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
PharmaCyte Biotech, Inc. (PMCB)
Price$0.4865Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2013
2014
2015
2016
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $12,160 | $66,558 | $125,997 |
| Gross profit | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $2,540 | $47,175 | $93,893 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | 20.89% | 70.88% | 74.52% |
| Research & development | $391,301 | $438,416 | $407,431 | $468,536 | $690,937 | $916,249 | $301,221 | $460,052 | $2.0M | $1.2M | $1.4M | $3.5M | $323,500 | $0 | — | — |
| Operating expenses | $6.9M | $4.4M | $8.5M | $6.5M | $4.4M | $3.6M | $3.8M | $4.1M | $7.0M | $4.4M | $6.1M | $13.3M | $19.0M | $1.7M | $2.0M | $482,254 |
| Operating income | −$6.9M | −$4.4M | −$8.5M | −$6.5M | −$4.4M | −$3.6M | −$3.8M | −$4.1M | −$7.0M | −$4.4M | −$6.1M | −$13.3M | −$19.0M | −$1.7M | −$1.9M | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | — | — | −13,851.65% | −2,928.55% | — |
| EBITDA | −$5.3M | −$4.4M | −$6.5M | −$6.5M | — | — | — | — | — | — | — | — | — | −$1.7M | −$1.9M | — |
| EBITDA margin | — | — | — | — | — | — | — | — | — | — | — | — | — | −13,851.65% | −2,891.50% | — |
| Net income | −$19.4M | $30.7M | $333,763 | −$4.3M | −$4.2M | −$3.6M | −$3.8M | −$4.1M | −$6.8M | −$4.4M | −$6.1M | −$9.9M | −$27.3M | −$1.6M | −$1.9M | −$1.4M |
| Net profit margin | — | — | — | — | — | — | — | — | — | — | — | — | — | −13,142.29% | −2,853.62% | −1,109.32% |
| Basic EPSper basic share | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$0.19 | -$0.33 | $0.00 | -$0.00 | -$0.00 | -$0.00 | -$0.00 | -$0.00 | $0.00 | -$0.00 | $0.00 |
| Diluted EPSper diluted share | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 | -$0.19 | -$0.33 | $0.00 | -$0.00 | -$0.00 | -$0.00 | -$0.00 | -$0.00 | $0.00 | — | — |
Owners
Reported shareholders
≈4.34%of listed shares
Silverman Joshua466.25K shares · Jan 7, 2026
View holders
| Holder | % owned |
|---|---|
Silverman Joshua | ≈4.34%466.25K shares |
CITADEL ADVISORS LLC | ≈2.64%283.38K shares |
SCHECHTER JONATHAN | ≈1.79%192.5K shares |
GEODE CAPITAL MANAGEMENT, LLC | ≈1.16%124.25K shares |
VANGUARD CAPITAL MANAGEMENT LLC | ≈0.53%56.78K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | ≈0.42%44.85K shares |
WEINSTEIN ROBERT | ≈0.38%41.25K shares |
RENAISSANCE TECHNOLOGIES LLC | ≈0.35%37.99K shares |
XTX Topco Ltd | ≈0.32%34.18K shares |
NORTHERN TRUST CORP | ≈0.30%32.62K shares |
JANE STREET GROUP, LLC | ≈0.28%30.06K shares |
Schonfeld Strategic Advisors LLC | ≈0.25%26.93K shares |
VANGUARD FIDUCIARY TRUST CO | ≈0.22%23.45K shares |
Abecassis Michael M | ≈0.22%23.09K shares |
EQUITEC PROPRIETARY MARKETS, LLC | ≈0.21%22.23K shares |
WALKER WAYNE REMELL | ≈0.19%20.63K shares |
COMMONWEALTH EQUITY SERVICES, LLC | ≈0.19%20.26K shares |
HRT FINANCIAL LP | ≈0.14%15.45K shares |
Tower Research Capital LLC (TRC) | ≈0.05%4.89K shares |
UBS Group AG | ≈0.04%4.14K shares |
Percentages use 10.74M shares of this listed class outstanding on Apr 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 7, 2026Form 4 | Silverman JoshuaCEO and President | BuyCommon Stock | 40.0K | $0.83 | $33.2K | 416.3K |
| Jan 7, 2026Form 4 | SCHECHTER JONATHANDirector | BuyCommon Stock | 20.0K | $0.84 | $16.8K | 192.5K |
| Jan 6, 2026Form 4 | Silverman JoshuaCEO and President | BuyCommon Stock | 30.0K | $0.79 | $23.7K | 376.3K |
| Jan 6, 2026Form 4 | SCHECHTER JONATHANDirector | BuyCommon Stock | 20.0K | $0.79 | $15.8K | 172.5K |
| Jan 5, 2026Form 4 | Silverman JoshuaCEO and President | BuyCommon Stock | 30.0K | $0.78 | $23.4K | 346.3K |